Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesUterine carcinosarcomas and grade 3 endometrioid cancers
Obstetrics and Gynecology, 07/03/08
Bansal N et al. - In a study to compare the clinical behavior and outcome of uterine carcinosarcomas and grade 3 endometrioid carcinomas, it was found that carcinosarcomas present at more advanced stage and have worse survival than grade 3 endometrioid carcinomas. Carcinosarcomas may represent a distinct biologic entity
Methods- Data on pts with grade 3 endometrioid adenocarcinomas and uterine carcinosarcomas was obtained from the SEER database
- Mortality was analyzed using Cox proportional hazards models
- Survival analysis was performed with the Kaplan-Meier method and log rank test
- The cohort included 8986 women with 5024 (56%) grade 3 endometrioid carcinomas and 3962 (44%) uterine carcinosarcomas
- Women with uterine carcinosarcomas were older and more often nonwhite
- These women presented with more advanced disease (stage III/IV 41% compared with 31%)
- Multivariable analysis demonstrated that uterine carcinosarcoma histology, advanced age, nonwhite race, and advanced stage were independent predictors of poor survival
- Cancer-specific mortality was 45% lower in women with grade 3 endometrioid carcinomas
- 5-year cancer-specific survival was lower for women with uterine carcinosarcoma for each disease stage
- Survival for stage IC was 38% for uterine carcinosarcoma compared with 68% for grade 3 endometrioid carcinoma
- For stage III, survival was 22% for uterine carcinosarcoma compared with 45% for grade 3 endometrioid carcinoma
| Previous Article | Next Article |
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Age-appropriate use of human papillomavirus vaccines in the US
Gynecologic Oncology, 06/30/09
Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
European Journal of Cancer, 06/15/09
Update: Endometrial Cancer
OBG Management, 07/02/09
Sponsor
Article Search
Sponsor